Publications in collaboration with researchers from Hospital Universitario de Valme (32)

2022

  1. IFNL4 genotype influences the rate of HIV-1 seroconversion in men who have sex with men

    Virulence, Vol. 13, Núm. 1, pp. 757-763

2021

  1. Cd46 genetic variability and hiv-1 infection susceptibility

    Cells, Vol. 10, Núm. 11

2020

  1. Association of complement C3d receptor 2 genotypes with the acquisition of HIV infection in a trial of recombinant glycoprotein 120 vaccine

    AIDS, Vol. 34, Núm. 1, pp. 25-32

  2. Toll-Like Receptor 2 Promoter -196 to -174 Deletion Affects CD4 Levels Along Human Immunodeficiency Virus Infection Progression

    The Journal of infectious diseases, Vol. 222, Núm. 12, pp. 2007-2011

2019

  1. Genetic associations of the vitamin D and antiviral pathways with natural resistance to HIV-1 infection are influenced by interpopulation variability

    Infection, Genetics and Evolution, Vol. 73, pp. 276-286

  2. Genetic markers of lipid metabolism genes associated with low susceptibility to HCV infection

    Scientific Reports, Vol. 9, Núm. 1

2015

  1. Longitudinal evaluation of hepatitis C viral persistence in HIV-infected patients with spontaneous hepatitis C clearance

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 34, Núm. 11, pp. 2171-2175

2014

  1. A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers

    Liver International, Vol. 34, Núm. 4, pp. 558-566

  2. Association of low-density lipoprotein receptor genotypes with hepatitis C viral load

    Genes and Immunity, Vol. 15, Núm. 1, pp. 16-24

  3. IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians

    PLoS ONE, Vol. 9, Núm. 4

2013

  1. A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients

    Journal of Antimicrobial Chemotherapy, Vol. 68, Núm. 4, pp. 915-921

  2. Association of BST-2 gene variants with HIV disease progression underscores the role of BST-2 in HIV type 1 infection

    Journal of Infectious Diseases, Vol. 207, Núm. 3, pp. 411-419

  3. Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV

    Infection, Vol. 41, Núm. 1, pp. 21-26

  4. Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 32, Núm. 11, pp. 1427-1435

  5. Natural Killer KIR3DS1 Is Closely Associated with HCV Viral Clearance and Sustained Virological Response in HIV/HCV Patients

    PLoS ONE, Vol. 8, Núm. 4

  6. Pegylated interferon plus ribavirin is suboptimal inIL28B CC carriers without rapid response

    Journal of Infection, Vol. 67, Núm. 1, pp. 59-64

  7. Short communication: Atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C

    AIDS Research and Human Retroviruses, Vol. 29, Núm. 2, pp. 223-225

  8. Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection

    AIDS, Vol. 27, Núm. 17, pp. 2715-2724

2012

  1. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 1, pp. 202-205

  2. Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients

    PLoS ONE, Vol. 7, Núm. 11